2015年1月20日訊 /生物谷BIOON/ --過繼性免疫治療主要是將活化之後具有殺傷性的免疫細胞轉輸或回輸給腫瘤病人，使其繼承特定的免疫能力，提高機體對抗腫瘤能力的一種新型療法。
由於過繼性免疫治療需要在體外培養並擴增來自患者體內的T細胞，故對臨床級細胞培養設備的要求極高。為了滿足這種T細胞治療的需求，需要大量人血清或胎牛血清，但是血清在生產運輸過程中有可能將接受免疫治療的患者暴露於偶然的感染病原體或被認為含有環鳥苷單磷酸而不適合用於過繼性免疫治療。
而來自Berghofer醫學研究所的研究者們開發了一套全新的無需外援血清置換細胞治療系統（Xeno-free CTS，xeno-free serum replacement cell therapy system）。為反覆產生臨床治療級的T細胞，該系統提供含有固定成分的養分並配合適合培養若干種不同種類細胞的培養基一共使用。在標記了CD3/CD28抗體的免疫磁珠或抗原特異性激活的T細胞增殖實驗中，無需外援血清置換細胞治療系統表現出與加入人血清或胎牛血清的細胞培養體系類似的T細胞生長曲線。更重要的是新型的治療系統所提供的培養條件極適合用於使針對次優腫瘤相關抗原的T細胞擴增，並在過繼性免疫治療之後促進患者體內產生持續起效的中心記憶T細胞種群。此外通過該系統擴增出的T細胞液非常適用於基於慢病毒載體轉染的基因改造技術。
綜上，無需外援血清置換細胞治療系統提供了一種新穎的製造臨床治療級過繼性T細胞的技術平臺，為將來更有效的腫瘤治療打下了堅實的基礎。（生物谷Bioon.com）
本文系生物谷原創編譯整理，歡迎轉載！轉載請註明來源並附原文連結。謝謝！
生物谷推薦的英文摘要：
Clinical & Translational Immunology doi:10.1038/cti.2014.31
新型過繼免疫治療術對抗腫瘤：Xeno-free細胞治療系統
Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement
Corey Smith1, Grethe ?kern2, Sweera Rehan1, Leone Beagley1, Sau K Lee1, Tanja Aarvak2, Karoline W Schjetne2 and Rajiv Khanna1
The manufacture of clinical grade cellular products for adoptive immunotherapy requires ex vivo culture and expansion of human T cells. One of the key components in manufacturing of T cell therapies is human serum (HS) or fetal bovine serum (FBS), which can potentially expose immunotherapy recipient to adventitious infectious pathogens and are thus considered as non-cGMP compliant for adoptive therapy. Here we describe a novel xeno-free serum replacement (SR) with defined components that can be reproducibly used for the production of clinical grade T-cell therapies in combination with several different cell culture media. Dynabeads CD3/CD28 Cell Therapy System (CTS)-activated or antigen-specific T cells expanded using the xeno-free SR, CTS Immune Cell SR, showed comparable growth kinetics observed with cell culture media supplemented with HS or FBS. Importantly the xeno-free SR supplemented medium supported the optimal expansion of T cells specific for subdominant tumour-associated antigens and promoted expansion of T cells with central memory T-cell phenotype, which is favourable for in vivo survival and persistence following adoptive transfer. Furthermore, T cells expanded using xeno-free SR medium were highly amenable to lentivirus-mediated gene transduction for potential application for gene-modified T cells. Taken together, the CTS Immune Cell SR provides a novel platform strategy for the manufacture of clinical grade adoptive cellular therapies.